Delcath Systems Inc logo

Delcath Systems Inc

NAS:DCTH (USA)  
$ 5.26 -0.19 (-3.49%) 10:08 PM EST
At Loss
P/B:
7.62
Market Cap:
$ 133.81M
Enterprise V:
$ 116.38M
Volume:
146.95K
Avg Vol (2M):
236.19K
Also Trade In:
Volume:
146.95K
At Loss
Avg Vol (2M):
236.19K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Delcath Systems Inc ( ) from 2000 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Delcath Systems stock (DCTH) PE ratio as of Apr 25 2024 is 0. More Details

Delcath Systems Inc (DCTH) PE Ratio (TTM) Chart

To

Delcath Systems Inc (DCTH) PE Ratio (TTM) Historical Data

Total 1215
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Delcath Systems PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-04-01 At Loss 2024-01-25 At Loss
2024-03-28 At Loss 2024-01-24 At Loss
2024-03-27 At Loss 2024-01-23 At Loss
2024-03-26 At Loss 2024-01-22 At Loss
2024-03-25 At Loss 2024-01-19 At Loss
2024-03-22 At Loss 2024-01-18 At Loss
2024-03-21 At Loss 2024-01-17 At Loss
2024-03-20 At Loss 2024-01-16 At Loss
2024-03-19 At Loss 2024-01-12 At Loss
2024-03-18 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-08 At Loss
2024-03-12 At Loss 2024-01-05 At Loss
2024-03-11 At Loss 2024-01-04 At Loss
2024-03-08 At Loss 2024-01-03 At Loss
2024-03-07 At Loss 2024-01-02 At Loss
2024-03-06 At Loss 2023-12-29 At Loss
2024-03-05 At Loss 2023-12-28 At Loss
2024-03-04 At Loss 2023-12-27 At Loss
2024-03-01 At Loss 2023-12-26 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss

Delcath Systems Inc (DCTH) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Delcath Systems Inc logo
Delcath Systems Inc
NAICS : 621511 SIC : 8071
ISIN : US24661P7087
Description
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.